AstraZeneca Pharma India share news, announcements and annual reports
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,364.50up ₹65.50 (1.04%)BSE ₹6,367.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹6,299.00.
30 Oct: open ₹6,300.00, high ₹6,380.00, low ₹6,240.50
52-week range of traded prices to 30 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,911 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 93.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,84556.8% delivered
AstraZeneca Pharma India orders, deals and press releases
23 filed, newest first.
Oct 2026
Aug 2026
11 Aug · Business
May 2026
Nov 2025
7 Nov · Business
Oct 2025
15 Oct · Business
3 Oct · Business
Aug 2025
14 Aug · Business
Feb 2025
11 Feb · Business
Nov 2024
Aug 2024
8 Aug · Business
May 2024
Mar 2024
Aug 2018
Jun 2018
Apr 2018
Mar 2016
Jun 2015
May 2015
Dec 2013
Apr 2010
1 Apr · Business
Press release dated April 01, 2010, titled "Bristol-Myers Squibb and AstraZeneca announce alliance to combat diabetes and launch of Onglyza (saxagliptin) in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
26 Jul · Business
At a meeting of the Board of Directors held on July 26, 2007 the Board - a) Took note of the resignation of Mr Ruud Dobber and Dr Henrik Nistrup Madsen as Directors from the Board of the Company w.e.f. July 26, 2007. b) Approved the appointment of Mr. Graham Baker and Mr. Bhasker Iyer as Directors in the casual vacancy caused by the resignations of Mr Ruud Dobber and Dr Henrik Nistrup Madsen, respectively, w.e.f. July 26, 2007. Further, at the said meeting, the Board also noted that the Hon'ble High Court of Karnataka, Bangalore, has passed an order approving the Scheme of Arrangement between the Company and its shareholders for issue of secured fully paid-up redeemable non-convertible bonus debentures from the Company's General Reserve; though a certified copy of the same is yet to be received. The Board further noted that the Company would initiate further steps on receipt of the certified copy and such further approvals as may be necessary for making the Scheme effective.